Lv41
440 积分 2024-11-11 加入
Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia
24天前
已完结
In Pursuit of Best-in-Class MCL-1 Inhibitors: Discovery of Highly Potent 1,4-Indoyl Macrocycles with Favorable Physicochemical Properties
24天前
已完结
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity
30天前
已完结
Sublethal engagement of apoptotic pathways in residual cancer
1个月前
已完结
Telomerase inhibitor imetelstat kills AML cells via lipid ROS and ferroptosis
1个月前
已完结
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
1个月前
已完结
Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies
1个月前
已完结
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
1个月前
已完结
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
1个月前
已完结
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
1个月前
已完结
皖公网安备34019202002308
